What Is Point-of-Care Testing? A Buyer's Hard-Learned Guide to Roche Diagnostics Products, Infusion Pumps, and Time Certainty

Let's get one thing out of the way: I'm not a clinician, and I'm not paid by Roche. I spent 11 years buying laboratory and near-patient equipment for community hospitals. During that time I personally made—and documented—22 significant procurement mistakes. Rough total: $214,000 in wasted budget and productivity, give or take. This FAQ is the checklist I wish I'd had before purchase order number one.

If you found this article because the phrase 'what is point of care testing' ended up on your screen, or because you are comparing Roche Diagnostics products for a health system, these are the questions that matter. Product details change; this was accurate as of January 2025. Verify current specifications before signing anything.

What is point-of-care testing (POCT)?

Point-of-care testing is a diagnostic test done at or near the patient, with a result meant to be used within the same clinical encounter. It can be a simple glucose meter, a coagulation device, a cardiac marker test, or an infectious disease test. The common thread is not the size of the device. It is speed and location: the result is supposed to change what happens immediately.

If the result is used in real time, it is point of care. If it gets filed for later, it is just a lab test.

That difference matters because some point-of-care devices look easy but still need integration, training, connectivity, quality control, and a plan for when they break. In 2018, I watched a hospital buy a beautiful POCT solution and then realize no one had checked whether results could flow to the electronic health record. The analyzers sat in a storage room for 19 days while IT sorted out interfaces. That delay wasn't a device failure; it was a project failure.

Should point-of-care testing replace the central laboratory?

I used to think faster was always better. Then I saw an emergency department buy extra POCT devices for tests that were already running well in the central lab. The result was duplicate testing, more documentation burden for nurses, and no obvious clinical gain.

POCT is best when the decision window is short and the patient is already where care happens. The central laboratory is better for high-throughput, complex work such as cultures, molecular identification, and broad chemistry panels. Roche Diagnostics products cover both sides of that equation, which can help when a hospital wants to standardize. But more near-patient testing is not automatically better care.

What makes Roche Diagnostics products different, and is brand enough?

Brand is never enough. I have bought expensive instruments that were a poor fit because of software, training, and service. I have also seen well-run labs choose Roche Diagnostics products because the installed base and test menu reduced risk. That reduction is real, but it must be proved in your environment.

'Roche Diagnostics products' usually means more than an analyzer. It includes instruments, reagents, software, service, and sometimes digital tools. If the quote says 'integration available,' ask what that means in writing. Available is not included. Ask about maintenance windows, loaner instruments, replacement parts, and training for night shift staff. Contract language is not marketing language.

Is Roche digital health AI diagnostics real or just hype?

Both, depending on what the product is meant to do. In one pilot I helped support, two departments handled the same POCT workflow differently. One manually wrote results down and entered them later. Another used middleware to send results automatically. The connected department had faster alerts and fewer missing results. That did not require artificial intelligence. It required disciplined data flow.

The AI diagnostics part becomes useful when it helps prioritize, flag, or interpret results in a way a human can act on. Before I evaluate any AI tool, I ask four questions:

1. What data was this trained on?
2. How does its sensitivity and specificity compare in a population similar to ours?
3. Does it have regulatory clearance or approval that covers this intended use?
4. What happens when the AI is uncertain or unavailable?

A vendor that cannot answer those questions is selling a PR deck, not a diagnostic tool. Roche digital health AI diagnostics is a broad portfolio; pick the specific piece that solves a named problem.

Why do infusion pumps and surgical instruments keep showing up in this conversation?

That question confused me too until I spent time mapping hospital workflows. Infusion pumps and surgical instruments do not perform diagnostics. They are downstream tools that depend on diagnostic decisions. The diagnosis determines what goes into the infusion pump, at what rate, and whether the patient should go to the operating room before a surgical instrument is used.

To be clear, I am not suggesting that Roche Diagnostics makes infusion pumps or surgical instruments. In my experience, the connection is clinical, not catalog. A hospital can have the best operating room equipment in the world and still lose time if the result that justifies surgery or medication arrives late.

In 2023, an elective procedure was delayed at my hospital because a fast confirmatory test could not be done in the preoperative area. The operating room team was ready. The surgical instrument setup was ready. The patient was waiting. The missing result caused a 70-minute delay. That block time cost more than many device service contracts I have negotiated. The diagnostic result sits between the patient and every treatment device.

What is the most common mistake when buying diagnostic products?

Comparing purchase prices instead of comparing failure consequences. I made this mistake in 2021. I selected a point-of-care analyzer because the capital price was lower. The instrument produced results fine, but it would not connect to our electronic health record without an additional interface package. The quote said 'integration available.' I read that as 'included.' It was not. The extra package cost roughly $11,200, and we spent three weeks on manual entry. The purchase price was not the project cost.

Now my team checks three things before sending a POCT or lab instrument order:

1. Total cost of ownership: instrument, consumables, training, interfaces, service, and downtime coverage.
2. Decision speed: when does the result actually need to reach the person acting on it?
3. Failure mode: what happens if the device is wrong, disconnected, or down? Who gets called and how fast is the response?

If a vendor cannot state the failure mode in plain language, I treat that as a red flag.

When is it worth paying more for certainty?

Whenever the cost of missing the decision window exceeds the premium. This is the lesson I keep repeating to my own procurement team.

In March 2024, I recommended a higher-priced analyzer because it came with priority support and a signed response-time commitment. The other proposal was about 5% cheaper. Six months later, the analyzer stopped with an error at 9:00 a.m. Priority support had the issue resolved by 11:30. If we had chosen the cheaper option with 'next business day' support, the afternoon clinic would have been canceled. The 5% saving would have produced a 100% disruption.

That same logic applies to urgent diagnostics. A POCT result requested at 2:00 a.m. is not served by a support line that is only staffed from 9 to 5. A rush reagent delivery is worth the premium if the alternative is no test at all for an unstable patient. These are not luxury upgrades; they are time-certainty decisions.

An uncertain cheap option is more expensive than a certain premium option when the penalty is a lost clinical decision window.

Only pay for certainty when the contract defines it. 'We try hard' is not a response-time target. 'Technical support available by phone within 30 minutes; replacement part delivered by next business day' is a promise you can evaluate. With diagnostics, a fair price is not the lowest number. It is the number that keeps the right result flowing at the right moment.